Central Nervous System (CNS) Stimulant Drug has its own characteristic mechanism of action on CNS neurones and their associated receptors and nerve terminals.

The global Central Nervous System (CNS) Stimulant Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Central Nervous System (CNS) Stimulant Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Central Nervous System (CNS) Stimulant Drugs.

Report Scope

The Central Nervous System (CNS) Stimulant Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Central Nervous System (CNS) Stimulant Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Central Nervous System (CNS) Stimulant Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Central Nervous System (CNS) Stimulant Drugs Market Report

Report Metric	Details
Report Name	Central Nervous System (CNS) Stimulant Drugs Market
CAGR	5%
Segment by Type	Amphetamine Cocaine Caffeine Others
Segment by Application	Attention Deficit Hyperactivity Disorder (ADHD) Narcolepsy Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Astellas Pharma, Biogen, Celltech, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Perdue Pharma, Pfizer, Roche, Sanofi, Shire, Takeda Pharmaceuticals, Thermo Fisher Scientific
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Central Nervous System (CNS) Stimulant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Central Nervous System (CNS) Stimulant Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Central Nervous System (CNS) Stimulant Drugs Market report?

Ans: The main players in the Central Nervous System (CNS) Stimulant Drugs Market are Astellas Pharma, Biogen, Celltech, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Perdue Pharma, Pfizer, Roche, Sanofi, Shire, Takeda Pharmaceuticals, Thermo Fisher Scientific

What are the Application segmentation covered in the Central Nervous System (CNS) Stimulant Drugs Market report?

Ans: The Applications covered in the Central Nervous System (CNS) Stimulant Drugs Market report are Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy, Others

What are the Type segmentation covered in the Central Nervous System (CNS) Stimulant Drugs Market report?

Ans: The Types covered in the Central Nervous System (CNS) Stimulant Drugs Market report are Amphetamine, Cocaine, Caffeine, Others

1 Central Nervous System (CNS) Stimulant Drugs Market Overview

1.1 Product Overview and Scope of Central Nervous System (CNS) Stimulant Drugs

1.2 Central Nervous System (CNS) Stimulant Drugs Segment by Type

1.2.1 Global Central Nervous System (CNS) Stimulant Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Amphetamine

1.2.3 Cocaine

1.2.4 Caffeine

1.2.5 Others

1.3 Central Nervous System (CNS) Stimulant Drugs Segment by Application

1.3.1 Global Central Nervous System (CNS) Stimulant Drugs Market Value by Application: (2024-2030)

1.3.2 Attention Deficit Hyperactivity Disorder (ADHD)

1.3.3 Narcolepsy

1.3.4 Others

1.4 Global Central Nervous System (CNS) Stimulant Drugs Market Size Estimates and Forecasts

1.4.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue 2019-2030

1.4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales 2019-2030

1.4.3 Global Central Nervous System (CNS) Stimulant Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Central Nervous System (CNS) Stimulant Drugs Market Competition by Manufacturers

2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Central Nervous System (CNS) Stimulant Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Central Nervous System (CNS) Stimulant Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Central Nervous System (CNS) Stimulant Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Central Nervous System (CNS) Stimulant Drugs, Product Type & Application

2.7 Central Nervous System (CNS) Stimulant Drugs Market Competitive Situation and Trends

2.7.1 Central Nervous System (CNS) Stimulant Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Central Nervous System (CNS) Stimulant Drugs Players Market Share by Revenue

2.7.3 Global Central Nervous System (CNS) Stimulant Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Central Nervous System (CNS) Stimulant Drugs Retrospective Market Scenario by Region

3.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Central Nervous System (CNS) Stimulant Drugs Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2019-2030

3.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2019-2024

3.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2025-2030

3.3 Global Central Nervous System (CNS) Stimulant Drugs Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2019-2030

3.3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2019-2024

3.3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2025-2030

3.4 North America Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Country

3.4.1 North America Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2030)

3.4.3 North America Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Country

3.5.1 Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2030)

3.5.3 Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Country

3.7.1 Latin America Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2030)

3.7.3 Latin America Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2019-2030)

4.1.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2019-2024)

4.1.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2025-2030)

4.1.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2019-2030)

4.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2019-2030)

4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2019-2024)

4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2025-2030)

4.2.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Central Nervous System (CNS) Stimulant Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2019-2030)

5.1.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2019-2024)

5.1.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2025-2030)

5.1.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2019-2030)

5.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2019-2030)

5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2019-2024)

5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2025-2030)

5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Central Nervous System (CNS) Stimulant Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Astellas Pharma

6.1.1 Astellas Pharma Corporation Information

6.1.2 Astellas Pharma Description and Business Overview

6.1.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.1.5 Astellas Pharma Recent Developments/Updates

6.2 Biogen

6.2.1 Biogen Corporation Information

6.2.2 Biogen Description and Business Overview

6.2.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.2.5 Biogen Recent Developments/Updates

6.3 Celltech

6.3.1 Celltech Corporation Information

6.3.2 Celltech Description and Business Overview

6.3.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.3.5 Celltech Recent Developments/Updates

6.4 Eli Lilly and Company

6.4.1 Eli Lilly and Company Corporation Information

6.4.2 Eli Lilly and Company Description and Business Overview

6.4.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.4.5 Eli Lilly and Company Recent Developments/Updates

6.5 GlaxoSmithKline

6.5.1 GlaxoSmithKline Corporation Information

6.5.2 GlaxoSmithKline Description and Business Overview

6.5.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.5.5 GlaxoSmithKline Recent Developments/Updates

6.6 Johnson and Johnson

6.6.1 Johnson and Johnson Corporation Information

6.6.2 Johnson and Johnson Description and Business Overview

6.6.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.6.5 Johnson and Johnson Recent Developments/Updates

6.7 Merck

6.6.1 Merck Corporation Information

6.6.2 Merck Description and Business Overview

6.6.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.7.5 Merck Recent Developments/Updates

6.8 Novartis

6.8.1 Novartis Corporation Information

6.8.2 Novartis Description and Business Overview

6.8.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.8.5 Novartis Recent Developments/Updates

6.9 Perdue Pharma

6.9.1 Perdue Pharma Corporation Information

6.9.2 Perdue Pharma Description and Business Overview

6.9.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.9.5 Perdue Pharma Recent Developments/Updates

6.10 Pfizer

6.10.1 Pfizer Corporation Information

6.10.2 Pfizer Description and Business Overview

6.10.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.10.5 Pfizer Recent Developments/Updates

6.11 Roche

6.11.1 Roche Corporation Information

6.11.2 Roche Central Nervous System (CNS) Stimulant Drugs Description and Business Overview

6.11.3 Roche Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.11.5 Roche Recent Developments/Updates

6.12 Sanofi

6.12.1 Sanofi Corporation Information

6.12.2 Sanofi Central Nervous System (CNS) Stimulant Drugs Description and Business Overview

6.12.3 Sanofi Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.12.5 Sanofi Recent Developments/Updates

6.13 Shire

6.13.1 Shire Corporation Information

6.13.2 Shire Central Nervous System (CNS) Stimulant Drugs Description and Business Overview

6.13.3 Shire Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.13.5 Shire Recent Developments/Updates

6.14 Takeda Pharmaceuticals

6.14.1 Takeda Pharmaceuticals Corporation Information

6.14.2 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Description and Business Overview

6.14.3 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.14.5 Takeda Pharmaceuticals Recent Developments/Updates

6.15 Thermo Fisher Scientific

6.15.1 Thermo Fisher Scientific Corporation Information

6.15.2 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Description and Business Overview

6.15.3 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio

6.15.5 Thermo Fisher Scientific Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Central Nervous System (CNS) Stimulant Drugs Industry Chain Analysis

7.2 Central Nervous System (CNS) Stimulant Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Central Nervous System (CNS) Stimulant Drugs Production Mode & Process

7.4 Central Nervous System (CNS) Stimulant Drugs Sales and Marketing

7.4.1 Central Nervous System (CNS) Stimulant Drugs Sales Channels

7.4.2 Central Nervous System (CNS) Stimulant Drugs Distributors

7.5 Central Nervous System (CNS) Stimulant Drugs Customers

8 Central Nervous System (CNS) Stimulant Drugs Market Dynamics

8.1 Central Nervous System (CNS) Stimulant Drugs Industry Trends

8.2 Central Nervous System (CNS) Stimulant Drugs Market Drivers

8.3 Central Nervous System (CNS) Stimulant Drugs Market Challenges

8.4 Central Nervous System (CNS) Stimulant Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astellas Pharma

Biogen

Celltech

Eli Lilly and Company

Takeda Pharmaceuticals

Thermo Fisher Scientific

List of Tables

Table 1. Global Central Nervous System (CNS) Stimulant Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Central Nervous System (CNS) Stimulant Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Central Nervous System (CNS) Stimulant Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Central Nervous System (CNS) Stimulant Drugs Sales (MT) of Key Manufacturers (2019-2024)

Table 5. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Central Nervous System (CNS) Stimulant Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Central Nervous System (CNS) Stimulant Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Central Nervous System (CNS) Stimulant Drugs Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Central Nervous System (CNS) Stimulant Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Central Nervous System (CNS) Stimulant Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Central Nervous System (CNS) Stimulant Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Central Nervous System (CNS) Stimulant Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Central Nervous System (CNS) Stimulant Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Stimulant Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Central Nervous System (CNS) Stimulant Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2019-2024) & (MT)

Table 18. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2025-2030) & (MT)

Table 20. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2024) & (MT)

Table 27. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2025-2030) & (MT)

Table 28. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2024) & (MT)

Table 32. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2025-2030) & (MT)

Table 33. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Region (2019-2024) & (MT)

Table 37. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Region (2025-2030) & (MT)

Table 38. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Central Nervous System (CNS) Stimulant Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2024) & (MT)

Table 42. Latin America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2025-2030) & (MT)

Table 43. Latin America Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2019-2024) & (MT)

Table 47. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2025-2030) & (MT)

Table 48. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Central Nervous System (CNS) Stimulant Drugs Sales (MT) by Type (2019-2024)

Table 51. Global Central Nervous System (CNS) Stimulant Drugs Sales (MT) by Type (2025-2030)

Table 52. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Central Nervous System (CNS) Stimulant Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Central Nervous System (CNS) Stimulant Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Central Nervous System (CNS) Stimulant Drugs Price (USD/MT) by Type (2019-2024)

Table 59. Global Central Nervous System (CNS) Stimulant Drugs Price (USD/MT) by Type (2025-2030)

Table 60. Global Central Nervous System (CNS) Stimulant Drugs Sales (MT) by Application (2019-2024)

Table 61. Global Central Nervous System (CNS) Stimulant Drugs Sales (MT) by Application (2025-2030)

Table 62. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Central Nervous System (CNS) Stimulant Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Central Nervous System (CNS) Stimulant Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Central Nervous System (CNS) Stimulant Drugs Price (USD/MT) by Application (2019-2024)

Table 69. Global Central Nervous System (CNS) Stimulant Drugs Price (USD/MT) by Application (2025-2030)

Table 70. Astellas Pharma Corporation Information

Table 71. Astellas Pharma Description and Business Overview

Table 72. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 73. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product

Table 74. Astellas Pharma Recent Developments/Updates

Table 75. Biogen Corporation Information

Table 76. Biogen Description and Business Overview

Table 77. Biogen Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 78. Biogen Central Nervous System (CNS) Stimulant Drugs Product

Table 79. Biogen Recent Developments/Updates

Table 80. Celltech Corporation Information

Table 81. Celltech Description and Business Overview

Table 82. Celltech Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 83. Celltech Central Nervous System (CNS) Stimulant Drugs Product

Table 84. Celltech Recent Developments/Updates

Table 85. Eli Lilly and Company Corporation Information

Table 86. Eli Lilly and Company Description and Business Overview

Table 87. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 88. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product

Table 89. Eli Lilly and Company Recent Developments/Updates

Table 90. GlaxoSmithKline Corporation Information

Table 91. GlaxoSmithKline Description and Business Overview

Table 92. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 93. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product

Table 94. GlaxoSmithKline Recent Developments/Updates

Table 95. Johnson and Johnson Corporation Information

Table 96. Johnson and Johnson Description and Business Overview

Table 97. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 98. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product

Table 99. Johnson and Johnson Recent Developments/Updates

Table 100. Merck Corporation Information

Table 101. Merck Description and Business Overview

Table 102. Merck Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 103. Merck Central Nervous System (CNS) Stimulant Drugs Product

Table 104. Merck Recent Developments/Updates

Table 105. Novartis Corporation Information

Table 106. Novartis Description and Business Overview

Table 107. Novartis Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 108. Novartis Central Nervous System (CNS) Stimulant Drugs Product

Table 109. Novartis Recent Developments/Updates

Table 110. Perdue Pharma Corporation Information

Table 111. Perdue Pharma Description and Business Overview

Table 112. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 113. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product

Table 114. Perdue Pharma Recent Developments/Updates

Table 115. Pfizer Corporation Information

Table 116. Pfizer Description and Business Overview

Table 117. Pfizer Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 118. Pfizer Central Nervous System (CNS) Stimulant Drugs Product

Table 119. Pfizer Recent Developments/Updates

Table 120. Roche Corporation Information

Table 121. Roche Description and Business Overview

Table 122. Roche Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 123. Roche Central Nervous System (CNS) Stimulant Drugs Product

Table 124. Roche Recent Developments/Updates

Table 125. Sanofi Corporation Information

Table 126. Sanofi Description and Business Overview

Table 127. Sanofi Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 128. Sanofi Central Nervous System (CNS) Stimulant Drugs Product

Table 129. Sanofi Recent Developments/Updates

Table 130. Shire Corporation Information

Table 131. Shire Description and Business Overview

Table 132. Shire Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 133. Shire Central Nervous System (CNS) Stimulant Drugs Product

Table 134. Shire Recent Developments/Updates

Table 135. Takeda Pharmaceuticals Corporation Information

Table 136. Takeda Pharmaceuticals Description and Business Overview

Table 137. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 138. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product

Table 139. Takeda Pharmaceuticals Recent Developments/Updates

Table 140. Thermo Fisher Scientific Corporation Information

Table 141. Thermo Fisher Scientific Description and Business Overview

Table 142. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 143. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product

Table 144. Thermo Fisher Scientific Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Central Nervous System (CNS) Stimulant Drugs Distributors List

Table 148. Central Nervous System (CNS) Stimulant Drugs Customers List

Table 149. Central Nervous System (CNS) Stimulant Drugs Market Trends

Table 150. Central Nervous System (CNS) Stimulant Drugs Market Drivers

Table 151. Central Nervous System (CNS) Stimulant Drugs Market Challenges

Table 152. Central Nervous System (CNS) Stimulant Drugs Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Central Nervous System (CNS) Stimulant Drugs

Figure 2. Global Central Nervous System (CNS) Stimulant Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Central Nervous System (CNS) Stimulant Drugs Market Share by Type in 2023 & 2030

Figure 4. Amphetamine Product Picture

Figure 5. Cocaine Product Picture

Figure 6. Caffeine Product Picture

Figure 7. Others Product Picture

Figure 8. Global Central Nervous System (CNS) Stimulant Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Central Nervous System (CNS) Stimulant Drugs Market Share by Application in 2023 & 2030

Figure 10. Attention Deficit Hyperactivity Disorder (ADHD)

Figure 11. Narcolepsy

Figure 12. Others

Figure 13. Global Central Nervous System (CNS) Stimulant Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Central Nervous System (CNS) Stimulant Drugs Market Size (2019-2030) & (US$ Million)

Figure 15. Global Central Nervous System (CNS) Stimulant Drugs Sales (2019-2030) & (MT)

Figure 16. Global Central Nervous System (CNS) Stimulant Drugs Average Price (USD/MT) & (2019-2030)

Figure 17. Central Nervous System (CNS) Stimulant Drugs Report Years Considered

Figure 18. Central Nervous System (CNS) Stimulant Drugs Sales Share by Manufacturers in 2023

Figure 19. Global Central Nervous System (CNS) Stimulant Drugs Revenue Share by Manufacturers in 2023

Figure 20. The Global 5 and 10 Largest Central Nervous System (CNS) Stimulant Drugs Players: Market Share by Revenue in 2023

Figure 21. Central Nervous System (CNS) Stimulant Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 22. Global Central Nervous System (CNS) Stimulant Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2019-2030)

Figure 24. North America Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Country (2019-2030)

Figure 25. U.S. Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2019-2030)

Figure 28. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Country (2019-2030)

Figure 29. Germany Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2019-2030)

Figure 36. China Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Taiwan Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Indonesia Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Thailand Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Malaysia Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Philippines Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Latin America Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2019-2030)

Figure 47. Latin America Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Country (2019-2030)

Figure 48. Mexico Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Brazil Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Argentina Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Country (2019-2030)

Figure 52. Middle East & Africa Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Country (2019-2030)

Figure 53. Turkey Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. U.A.E Central Nervous System (CNS) Stimulant Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Global Sales Market Share of Central Nervous System (CNS) Stimulant Drugs by Type (2019-2030)

Figure 57. Global Revenue Market Share of Central Nervous System (CNS) Stimulant Drugs by Type (2019-2030)

Figure 58. Global Central Nervous System (CNS) Stimulant Drugs Price (USD/MT) by Type (2019-2030)

Figure 59. Global Sales Market Share of Central Nervous System (CNS) Stimulant Drugs by Application (2019-2030)

Figure 60. Global Revenue Market Share of Central Nervous System (CNS) Stimulant Drugs by Application (2019-2030)

Figure 61. Global Central Nervous System (CNS) Stimulant Drugs Price (USD/MT) by Application (2019-2030)

Figure 62. Central Nervous System (CNS) Stimulant Drugs Value Chain

Figure 63. Central Nervous System (CNS) Stimulant Drugs Production Process

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Distributors Profiles

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions